Pedro Rafael Gómez dreamed of becoming an interior designer. Relocating to Portland provided him with the perfect first canvas. By Tim McKeough Andrew Forsyth, who works in commercial real estate, is ...

Controversial rapper and entrepreneur Kanye West is suing his former employee and his attorneys for placing a lien on his onetime Malibu mansion purchased for $57 million and then gutted and sold.

Ali Primera sang songs of resistance to inequality and injustice—songs of resistance to the United States. And he had reason to be wary of the US: He says his torturers were instructed by US officials ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Troy Segal is an editor and writer. She has 20+ years of experience covering personal finance, wealth management, and business news. Gordon Scott has been an active investor and technical analyst or ...

Author Shawn Peters blends clarity and rigor to make data structures and algorithms accessible to all learners. COLORADO, CO, UNITED STATES, January 2, 2026 /EINPresswire.com/ — Vibrant Publishers ...

Find out why real estate is considered a good investment Barclay Palmer is a creative executive with 10+ years of creating or managing premium programming and brands/businesses across various ...

MIT’s Recursive Language Models rethink AI memory by treating documents like searchable environments, enabling models to ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...